FI962591A0 - Föreningar med tillväxthormonfrigörande egenskaper - Google Patents

Föreningar med tillväxthormonfrigörande egenskaper

Info

Publication number
FI962591A0
FI962591A0 FI962591A FI962591A FI962591A0 FI 962591 A0 FI962591 A0 FI 962591A0 FI 962591 A FI962591 A FI 962591A FI 962591 A FI962591 A FI 962591A FI 962591 A0 FI962591 A0 FI 962591A0
Authority
FI
Finland
Prior art keywords
growth hormone
pct
hormone releasing
compounds
date jun
Prior art date
Application number
FI962591A
Other languages
English (en)
Finnish (fi)
Other versions
FI962591A (sv
Inventor
Nils Langeland Johansen
Jesper Lau
Kjeld Madsen
Behrend Friedrich Lundt
Henning Thoegersen
Birgit Sehested Hansen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK143893A external-priority patent/DK143893D0/da
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of FI962591A publication Critical patent/FI962591A/sv
Publication of FI962591A0 publication Critical patent/FI962591A0/sv

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/60Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/02Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0812Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1002Tetrapeptides with the first amino acid being neutral
    • C07K5/1005Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02Linear peptides containing at least one abnormal peptide link
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FI962591A 1993-12-23 1996-06-20 Föreningar med tillväxthormonfrigörande egenskaper FI962591A0 (sv)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DK143893A DK143893D0 (sv) 1993-12-23 1993-12-23
DK7594 1994-01-17
DK78194 1994-06-30
DK116594 1994-10-07
PCT/DK1994/000486 WO1995017422A1 (en) 1993-12-23 1994-12-22 Compounds with growth hormone releasing properties

Publications (2)

Publication Number Publication Date
FI962591A FI962591A (sv) 1996-06-20
FI962591A0 true FI962591A0 (sv) 1996-06-20

Family

ID=27439242

Family Applications (1)

Application Number Title Priority Date Filing Date
FI962591A FI962591A0 (sv) 1993-12-23 1996-06-20 Föreningar med tillväxthormonfrigörande egenskaper

Country Status (18)

Country Link
US (1) US5854211A (sv)
EP (1) EP0736038B1 (sv)
JP (1) JP3759748B2 (sv)
CN (1) CN1052730C (sv)
AT (1) ATE202785T1 (sv)
AU (1) AU683121B2 (sv)
CA (1) CA2179598A1 (sv)
CZ (1) CZ291382B6 (sv)
DE (1) DE69427650T2 (sv)
FI (1) FI962591A0 (sv)
HU (1) HU221092B1 (sv)
IL (1) IL112111A (sv)
NO (1) NO315611B1 (sv)
PL (1) PL181286B1 (sv)
RU (1) RU2167881C2 (sv)
TW (1) TW438810B (sv)
UA (1) UA45962C2 (sv)
WO (1) WO1995017422A1 (sv)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU684878B2 (en) * 1993-11-24 1998-01-08 Merck & Co., Inc. Compounds and the use thereof to promote the release of growth hormone(s)
US6242199B1 (en) 1995-12-13 2001-06-05 Merck & Co., Inc. Assays for growth hormone secretagogue receptors
US6531314B1 (en) 1996-12-10 2003-03-11 Merck & Co., Inc. Growth hormone secretagogue receptor family
GB2308362A (en) * 1995-12-19 1997-06-25 Lilly Industries Ltd Pharmaceutical indole derivatives
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
WO1998058950A1 (en) 1997-06-20 1998-12-30 Novo Nordisk A/S Compounds with growth hormone releasing properties
WO1999036431A1 (en) 1998-01-16 1999-07-22 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6682908B1 (en) 1998-07-10 2004-01-27 Merck & Co., Inc. Mouse growth hormone secretagogue receptor
EP1097170A1 (en) 1998-07-13 2001-05-09 Merck & Co., Inc. Growth hormone secretagogue related receptors and nucleic acids
US6645726B1 (en) 1998-08-10 2003-11-11 Merck & Co., Inc. Canine growth hormone secretagogue receptor
JP3971108B2 (ja) 1999-01-06 2007-09-05 ジェネンテック・インコーポレーテッド インシュリン様成長因子(igf)i突然変異体
CN1157224C (zh) 1999-02-18 2004-07-14 科研制药株式会社 用作生长激素促分泌剂的新酰胺衍生物
US6551998B1 (en) * 1999-06-22 2003-04-22 University Of Louisville Research Foundation, Inc. Antimicrobial agents
EP1204321B1 (en) 1999-07-26 2005-11-09 Baylor College Of Medicine Super-active porcine growth hormone releasing hormone analog
US6737420B2 (en) * 2000-03-23 2004-05-18 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
WO2001087323A2 (en) 2000-05-16 2001-11-22 Genentech, Inc. Method for treating cartilage disorders
ES2333097T3 (es) 2000-05-31 2010-02-17 Raqualia Pharma Inc Uso de secretagogos de la hormona de crecimiento para estimular la motilidad gastrointestinal.
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
ES2541673T3 (es) 2003-09-12 2015-07-23 Ipsen Biopharmaceuticals, Inc. Métodos para el tratamiento de la deficiencia de factor 1 de crecimiento similar a la insulina (IGF-1)
WO2005027913A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a growth hormone secretagogue
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
ES2602789T3 (es) 2007-02-09 2017-02-22 Ocera Therapeutics, Inc. Productos intermedios conectores para la síntesis de moduladores macrocíclicos del receptor de la grelina
US20100099640A1 (en) 2007-05-04 2010-04-22 Joannes Geuns Tissue degeneration protection
WO2013190520A2 (en) 2012-06-22 2013-12-27 The General Hospital Corporation Gh-releasing agents in the treatment of vascular stenosis and associated conditions
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
KR20160147007A (ko) 2014-05-30 2016-12-21 화이자 인코포레이티드 선택적인 안드로겐 수용체 조절제로서의 카보니트릴 유도체
WO2016129645A1 (ja) 2015-02-10 2016-08-18 富士フイルム株式会社 光学部材、光学素子、液晶表示装置および近接眼光学部材
US20170121385A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4803261A (en) * 1986-06-27 1989-02-07 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide
US5480869A (en) * 1990-01-09 1996-01-02 The Regents Of The University Of California Anti-inflammatory peptide analogs and treatment to inhibit vascular leakage in injured tissues
IL98910A0 (en) * 1990-07-24 1992-07-15 Polygen Holding Corp Polypeptide compounds having growth hormone releasing activity and pharmaceutical compositions containing them
US5486505A (en) * 1990-07-24 1996-01-23 Polygen Holding Corporation Polypeptide compounds having growth hormone releasing activity
US5663146A (en) * 1991-08-22 1997-09-02 Administrators Of The Tulane Educational Fund Polypeptide analogues having growth hormone releasing activity
US5470753A (en) * 1992-09-03 1995-11-28 Selectide Corporation Peptide sequencing using mass spectrometry
SE9300012D0 (sv) * 1993-01-05 1993-01-05 Astra Ab New peptides
US5559209A (en) * 1993-02-18 1996-09-24 The General Hospital Corporation Regulator regions of G proteins
SK281963B6 (sk) * 1993-12-23 2001-09-11 Novo Nordisk A/S Zlúčeniny ovplyvňujúce uvoľňovanie rastového hormónu, farmaceutické prostriedky s ich obsahom a ich použitie

Also Published As

Publication number Publication date
AU683121B2 (en) 1997-10-30
EP0736038B1 (en) 2001-07-04
DE69427650D1 (de) 2001-08-09
CN1052730C (zh) 2000-05-24
UA45962C2 (uk) 2002-05-15
PL315114A1 (en) 1996-10-14
IL112111A0 (en) 1995-03-15
CA2179598A1 (en) 1995-06-29
HU221092B1 (en) 2002-08-28
CZ183396A3 (en) 1997-02-12
NO962664L (no) 1996-08-23
AU1310695A (en) 1995-07-10
ATE202785T1 (de) 2001-07-15
NO962664D0 (no) 1996-06-21
FI962591A (sv) 1996-06-20
HUT74820A (en) 1997-02-28
TW438810B (en) 2001-06-07
WO1995017422A1 (en) 1995-06-29
US5854211A (en) 1998-12-29
IL112111A (en) 2000-07-16
RU2167881C2 (ru) 2001-05-27
CN1138334A (zh) 1996-12-18
CZ291382B6 (cs) 2003-02-12
JPH09506873A (ja) 1997-07-08
PL181286B1 (pl) 2001-07-31
JP3759748B2 (ja) 2006-03-29
HU9601740D0 (en) 1996-08-28
NO315611B1 (no) 2003-09-29
DE69427650T2 (de) 2001-11-22
EP0736038A1 (en) 1996-10-09

Similar Documents

Publication Publication Date Title
NO962664L (no) Forbindelser med veksthormonfrigjörende egenskaper
ATE188379T1 (de) Fibrinogenrezeptor-antagonisten
PT804252E (pt) Agentes queladores metalicos que contem monoaminas diamidas e tiois
ATE185548T1 (de) Verwendung von n-arylmethylen ethylendiamintriacetate, n-arylmethylen iminodiacetat oder n,n'-diarylmethylen ethylendiamindiacetat gegen oxidativen stress
DE69507029D1 (de) Pharmazeutische zusammensetzungen enthaltend einen opiat antagonist und calcium salze, ihre verwendung zur behandlung von endorphin-vermittelten krankheiten
FI964332A (sv) Användning av vissa metanbisfofonsyraderivat för att hindra förslappning och vandring av protes
ATE211384T1 (de) Verwendung von adenosinantagonisten zur vorbeugung und behandlung von pankreatitis und ulcera
DK1077941T3 (da) Forbindelser med væksthormonfrigörende egenskaber
IL126235A (en) Compounds with growth hormone releasing properties, pharmaceutical compositions comprising them and their use
DE69530988D1 (de) Benzimidazolderivate mit dopaminerger wirkung
NO20010940L (no) TAN-1057 derivater
MX9604762A (es) Nuevas sulfonamidas y procedimiento para su preparacion.
DE60035133D1 (de) Pharmazeutische zusammensetzungen mit wundheilender und anti-komplementärer wirkung die ein dextranderivat enthalten
DK1100824T3 (da) Forbindelser med væksthormonfrigivende egenskaber
DE69531150D1 (de) Verwendung von biopolymeren zur behandlung der muskeln
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
DK0842193T3 (da) Somatostatin-analoge cykliske peptider med hæmmende aktivitet på væksthormon
EA199700032A1 (ru) Дезинфицирующий состав "велтолен"
NO20012169D0 (no) Forbindelser med veksthormonfrigjörende egenskaper
ATE224716T1 (de) Pharmazeutische zusammensetzungen von cinchonin dihydrochlorid
DE69503635D1 (de) Pyrrolidinderivate zur behandlung von cck und gastrin-abhängigen erkrankungen
TH32887A (th) สารประกอบทางเคมี

Legal Events

Date Code Title Description
MA Patent expired